by Elec23 | Dec 5, 2025 | News&events
A new scientific paper authored by Emanuele Montomoli and Claudia Maria Trombetta has just been published in Expert Review of Vaccines: “High-dose influenza vaccine: enhanced protection for the elderly.” The review highlights the added value of the high-dose influenza...
by Elec23 | Dec 3, 2025 | News&events
VisMederi is pleased to announce the establishment of VisMederi America, a new company based in Cleveland that marks a strategic milestone in the Group’s expansion into the United States. The new entity aims to strengthen VisMederi’s international presence,...
by Elec23 | Nov 27, 2025 | News&events
VisMederi is once again included in the “Leader of Growth 2026” ranking compiled by Il Sole 24 Ore in collaboration with Statista, where it ranks among the Italian companies that have performed the best in terms of revenue growth and development over the...
by Elec23 | Oct 23, 2025 | News&events
We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines. VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the...
by Elec23 | Oct 17, 2025 | News&events
Our team wrapped up an inspiring and productive week at the World Vaccine Congress Europe 2025 in Amsterdam — the leading European event dedicated to vaccines, held from October 13 to 16 at the RAI Congress Center. It was an invaluable opportunity to engage with some...
